Published in Cancer Weekly, May 22nd, 2007
Each partner brings specific strengths to the project, creating a strong R&D collaboration. Biocrates' strengths lie in targeted metabolomics. Brad Morie, Chief Business Development Officer at Biocrates, said "This project comes at a perfect time for us. We have officially launched our proprietary targeted metabolomics services platform, TargetIDQ(TM). TargetIDQ(TM) has proven effective in our collaborations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.